BioSpace News Archive

Connect Biopharma Holdings Limited announced the appointments of Barry Quart, Pharm.D., as Chief Executive Officer and Director, David Szekeres as President, and Kleanthis G. Xanthopoulos, Ph.D., as the new Chair of the Board of Directors.

DENTSPLY SIRONA Inc. announced that it is canceling its participation in the Goldman Sachs 45th Annual Global Healthcare Conference due to weather-related flight disruptions.

Innovent Biologics, Inc. announced that the U.S. Food and Drug Administration has granted Fast Track Designation to its TOPO1i anti-CLDN18.2 ADC, for the treatment of advanced unresectable or metastatic pancreatic ductal adenocarcinoma that has relapsed and/or is refractory to one prior line of therapy.

With a career dedicated to delivering firsts in medicine and innovating to find new ways to treat patients, McKerracher’s expertise will help Genialis commercialize first-in-class biomarkers.

Simulations Plus, Inc. announced the acquisition of Pro-ficiency Holdings, Inc. and its subsidiaries, a leader in providing simulation-enabled performance and intelligence solutions for clinical and commercial drug development.

bioAffinity Technologies, Inc., a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, reported 139% growth in the number of pulmonology practices and physicians offering CyPath® Lung to patients since Jan. 1, 2024.

BioVie Inc. is pleased to invite investors to a webinar on June 26, 2024, at 4:15 p.m. ET.

Cranbury Pharmaceuticals (Cranbury), a wholly-owned subsidiary of Tris Pharma, today announced the U.S. Food and Drug Administration (FDA) approved the Abbreviated New Drug Application (ANDA) for the first generic version of Emflaza® oral suspension (deflazacort) for the treatment of Duchenne muscular dystrophy (DMD).

RevelAi Health and Zimmer Biomet Holdings, Inc., a global medical technology leader, announced a multi-year co-marketing agreement to commercialize generative artificial intelligence -powered engagement solutions that advance value-based orthopedic care and health equity.

MIB Agents, a leading pediatric osteosarcoma nonprofit dedicated to Making It Better for its community of patients, caregivers, doctors, and researchers, announced that since its inception in 2016, it has awarded over $1.9 million to scientists across the country through its OutSmarting Osteosarcoma grant program.